Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a minority of claims are supported by the provided FDA label excerpts. Many claims about generic equivalence, switching practices, insurance coverage, and confirming active ingredient are not supported by the supplied label sections, leading to poor alignment.
Category Scores
Accurate Statements
Evista is the brand name for raloxifene.
Supported (11 DESCRIPTION: EVISTA (raloxifene hydrochloride))
Raloxifene is associated with a risk of blood clots.
Supported (1 INDICATIONS AND USAGE section includes WARNING: increased risk of deep vein thrombosis and pulmonary embolism)
Raloxifene is associated with a risk of stroke.
Supported (1 INDICATIONS AND USAGE section includes WARNING: increased risk of death from stroke)
Raloxifene is prescribed with consideration of benefit vs risk in women at risk for stroke.
Partially supported (1 INDICATIONS AND USAGE includes: Consider risk-benefit balance in women at risk for stroke)
The generic name to search for is raloxifene, often as raloxifene hydrochloride.
Supported (11 DESCRIPTION: EVISTA (raloxifene hydrochloride) and product formulation description)
Generic raloxifene comes in tablet strengths that correspond to Evista’s common strengths.
Partially supported at most (11 DESCRIPTION specifies EVISTA contains 60 mg raloxifene HCl; correspondence to generic strengths is not established in provided excerpts)
Because generic and brand use the same active ingredient, the key warnings and side effects that apply to Evista also apply to generic raloxifene.
Partially supported (11 DESCRIPTION and warning text reference EVISTA’s active ingredient; statement about warnings/side effects applying to generics is not explicitly supported)
Unsupported Statements
Generic versions of Evista are made with the same active ingredient, raloxifene hydrochloride.
Not supported by the provided label excerpts.
Generics are expected to match Evista’s active ingredient.
Not supported by the provided label excerpts.
Generics are required to meet FDA bioequivalence requirements.
Not supported by the provided label excerpts.
FDA bioequivalence is intended to provide similar clinical effect and safety when used as prescribed.
Not supported by the provided label excerpts.
Patients should match the mg strength on the prescription rather than just the brand name.
Not supported by the provided label excerpts.
In many cases, patients can switch from Evista to generic raloxifene at the same dose.
Not supported by the provided label excerpts.
The safest approach to switching includes doing it through the prescriber ... or through the pharmacist to confirm exact strength and that it is the same active ingredient.
Not supported by the provided label excerpts.
Generic raloxifene is typically much cheaper than brand-name Evista.
Not supported by the provided label excerpts.
Many insurance plans prefer generics and may require prior authorization or a higher copay for brand Evista unless there is a documented reason a patient cannot take the generic.
Not supported by the provided label excerpts.
Some websites may list other osteoporosis or hormone-related medicines.
Not supported by the provided label excerpts.
Active ingredient raloxifene must be confirmed before assuming a product is the Evista generic.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
No evaluation of label contraindications and other safety-critical labeling beyond the limited warning excerpts was performed against the provided claim list (e.g., contraindicated patient populations/pregnancy-related contraindications).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several statements provide guidance about switching and equivalence that are not supported by the provided label excerpts; this increases the chance of label-inconsistent handling even though key risks of VTE and stroke were correctly identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple generic-switching, equivalence, and practical substitution claims are not supported by the supplied FDA label sections.
Suggested Improvement
Restrict assertions to what is explicitly supported by the provided label excerpts (e.g., EVISTA contains raloxifene HCl; risks of VTE and stroke). Remove or rephrase statements about bioequivalence, switching at the same dose, confirming generics/active ingredient, and insurance/cost considerations unless supported by the provided label.